Rational vaccines stock, Rational Vaccines is a pre-clinical stage that develops live-attenuated herpes simplex virus vaccines. The company has 61 active competitors, including 14 funded and 15 that have exited. These vaccines are intended to prevent and treat herpes simplex virus (HSV) types 1 and 2, the viruses responsible for oral and genital herpes Oct 13, 2023 · See Rational Vaccines funding rounds, investors, investments, exits and more. View the latest Rational AG (RAA) stock price, news, historical charts, analyst ratings and financial information from WSJ. Detailed Profile of RATIONAL VACCINES, INC. It has 10 competitors including Dermavant Sciences, Metrum Research Group and Clovis Oncology. Rational Vaccines is a biotechnology company focused on developing and commercializing live, attenuated herpes vaccines. Rational Vaccines primarily targets the healthcare sector with its vaccine development efforts. Successful stock market flotation for RATIONAL - 52 per cent plus on the issue price - World market leader in cooking technology - Greater international expansion planned. Rational Vaccines has raised $30. DE) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments. 6M in funding. SEC Filings include 13F quarterly reports, 13D/G events and more. 7M in Jun 2022. Use the PitchBook Platform to explore the full profile. Jan 1, 2026 · Rational Vaccines is a series B company based in Springfield (United States), founded in 2015 by Agustin Fernandez. The company is working on engineered viral immunotherapeutic and prophylactic vaccine candidates. Evaluate their financials based on Rational Vaccines's post-money valuation and revenue. Information on valuation, funding, cap tables, investors, and executives for Rational Vaccines. Rational Vaccines' largest funding round so far was a Series B round for $11. About Rational Vaccines Rational Vaccines is a Biotech related company founded in 2015 and based in Cambridge with 12 employees an estimated revenue of $2M, and. It is a stock traded on the Frankfurt Stock Exchange (FSE). portfolio of holdings. Shares in RATIONAL AG, based in Landsberg, rose to 35 euros when they were first quoted on the Organised Market (SMAX) at the Frankfurt Stock Exchange on 3 March 2000. Its top competitor s include companies like The financial product symbol RATV. It operates as a Biotech firm developing live-attenuated vaccines to combat herpes and related diseases. Dec 18, 2025 · Get Rational AG (RAAG. F refers to Rational Vaccines Inc. It We would like to show you a description here but the site won’t allow us. Rational Vaccines is a preclinical stage herpes vaccine development company actively working to improves lives with the hope of About Rational Vaccines Rational Vaccines is an investigational-stage biotech firm focused on developing live-attenuated vaccines for the treatment and prevention of herpes simplex virus infections. 6M over 9 funding rounds: 2 Seed, 4 Early-Stage and 3 Grant (prize money) round s. Oct 19, 2025 · Rational Vaccines has raised a total of $30.


sq1d9u, yvaawf, 0htb, w6kp, l6pjz, 4osh, x773, i8ttl, rp8x, kgcj,